Search clinical trials for: BQ-123 and BQ-788

Total 2169 results

The Netherlands Cancer Institute
Bayer

Completed

Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223 (ROTOR)

Bone Metastases | Prostate Cancer Metastatic

Netherlands
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne

United States
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne

United States
Memorial Sloan Kettering Cancer Center
Johns Hopkins University; M.D. Anderson Cancer Center

Completed

A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer

Ovarian Cancer

United States
University of California, Los Angeles
National Institute of Allergy and Infectious Diseases (NIAID); CONRAD

Completed

Safety and Acceptability Study of the UC-781 Microbicide Gel Applied Rectally

HIV Infections

United States
Bayer

Completed

BAY88-8223, Dose Finding Study in Patients With HRPC

Neoplasm Metastasis | Prostate Cancer

United Kingdom
Bayer

Completed

A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety (QOLRAD)

Prostate Cancer

Colombia
Bayer

Completed

Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany (URANIS)

Prostatic Neoplasms, Castration-Resistant

Germany
Vicus Therapeutics

Completed

Regimen for the Treatment of Cachexia in Subjects With NSCLC (VT-122)

Cachexia

India, United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants

Acute Pain

United Kingdom
Carolina Research Professionals, LLC
Astellas Pharma Inc

Completed

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

Prostate Carcinoma Metastatic to the Bone

United States
Huazhong University of Science and Technology

Unknown

Study of Molecular-targeted Therapy Using Zinc Finger Nuclease in Cervical Precancerous Lesions

Human Papillomavirus-Related Malignant Neoplasm

China
Huahui Health

Completed

A Study to Evaluate the Safety and Pharmacokinetics of HH-120 Nasal Spray in Healthy Volunteers

COVID-19

China
Valeant Pharmaceuticals

Unknown

Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris

Acne Vulgaris
Nobelpharma

Active, not recruiting

Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC

Tuberous Sclerosis Complex

Japan
Transwell Biotech Co., Ltd.
A2 Healthcare Taiwan Corporation

Completed

TWB-103 for Adult Patients With Split-Thickness Skin Graft Donor Site Wounds

Donor Site Complication

Japan, Taiwan
Bayer

Completed

Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

Prostate Cancer | Pharmacokinetics | Metastases

United States
CONRAD
Emory University; Centers for Disease Control and Prevention

Completed

Study of UC-781 Vaginal Microbicide

HIV Infections

United States
ModernaTX, Inc.
National Institute of Allergy and Infectious Diseases (NIAID); Biomedical Advanced...

Completed

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

SARS-CoV-2

United States
Thryv Therapeutics, Inc.

Completed

Phase 1 Study of LQT-1213 in Healthy Adults

Long QT Syndrome

United States
E-DA Hospital

Unknown

The Prognostic and Predictive Value of the CA-125 Marker in Lung Cancer Monitoring

Lung Cancer

Taiwan
AbbVie (prior sponsor, Abbott)

Completed

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Alzheimer's Disease

United States, Canada, France, Germany, Greece, South Africa, United Kingdom
OBI Pharma, Inc

Terminated

This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, Taiwan
PH Research, S.L.

Completed

Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer (FRAGANCE)

Advanced Pancreatic Cancer

Spain
Meiji University of Oriental Medicine
Kyoto Prefectural University of Medicine

Terminated

Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan

Allergic Conjunctivitis

Japan
Celgene

Terminated

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Lymphoma, Large B-Cell, Diffuse

United States, France, Canada, Italy
Santen Inc.

Completed

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Open-angle Glaucoma, Ocular Hypertension

United States, Japan
Sumitomo Pharma America, Inc.

Completed

A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies

Melanoma | Sarcoma | Renal Cell Carcinoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Glioblastoma Multiforme

United States
Sage Therapeutics

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B

Huntington Disease

United States
Cocrystal Pharma, Inc.
Cocrystal Pharma Australia Pty Ltd.; Nucleus Network Pty Ltd.; Beyond Drug Development... and other collaborators

Recruiting

CDI-988 Safety Study in Healthy Participants

Healthy Volunteers

Australia
National Institute of Allergy and Infectious Diseases...
ModernaTX, Inc.

Completed

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

COVID-19 | COVID-19 Immunisation

United States
H. Lee Moffitt Cancer Center and Research Institute
ModernaTX, Inc.

Completed

COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

Covid19 | SARS-CoV2 Infection

United States
Institute for Neurodegenerative Disorders
National Institutes of Health (NIH); Molecular NeuroImaging

Completed

Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome

Parkinson's Disease | Parkinsonian Syndrome
ModernaTX, Inc.

Recruiting

A Study of the Effectiveness of Moderna COVID-19 Vaccine

COVID-19 | SARS-CoV-2

United States
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France

Not yet recruiting

Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y) (CoviCompareM)

Prevention of COVID19
Medeor Therapeutics, Inc.

Not yet recruiting

Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants

Kidney Transplant Rejection
CASI Pharmaceuticals, Inc.

Active, not recruiting

CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United Kingdom, France
Maria Joyera Rodríguez

Withdrawn

Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination (VAX-TRES)

Covid19
Bayer

Active, not recruiting

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer (REASSURE)

Metastatic Castration-resistant Prostate Cancer

United States, Austria, Czechia, Israel, Italy, Germany, United Kingdom, France, Mexico, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Denmark, Sweden, Argentina, Portugal
Bayer

Completed

BAY88-8223, Does Response Study in HRPC Patients

Bone Metastases | Hormone Refractory Prostate Cancer
Bayer

Completed

Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population

Prostate Cancer

United States
Bayer

Completed

Treatment Patterns in Metastatic Prostate Cancer

Prostatic Neoplasm

United States
Bayer

Completed

Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases

Neoplasm Metastasis

Sweden, Norway
Bayer

Completed

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

Neoplasm Metastasis | Prostate Cancer

Sweden, United Kingdom
University of Utah
Bayer

Completed

Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone (RROPE)

Prostate Cancer Metastatic to Bone

United States
Bayer

Completed

Treatment Satisfaction With Ra-223 in Japan

Prostatic Neoplasms

Japan
Bayer

Terminated

A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels (CREDIT)

Bone Metastases | Metastatic Castration-resistant Prostate Cancer

China
Bayer

Completed

Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases (PARABO)

Castration-Resistant Prostatic Cancer

Germany
Bayer

Completed

Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases

Prostatic Neoplasms

United States, Israel, Spain, Italy, Sweden, Norway, Finland

3

Subscribe